Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikhail Y Samsonov

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|June 9, 2025
Targeting interleukin-1 signaling for renoprotectionDaria Bogdanova, Mikhail Y Samsonov, Svetlana Lebedeva, et al.
Frontiers in Immunology|December 26, 2024
Targeting inerleukin-6 for renoprotectionEkaterina O Gubernatorova, Mikhail Y Samsonov, Marina S Drutskaya, et al.
The New England Journal of Medicine|August 24, 2022
Olokizumab versus Placebo or Adalimumab in Rheumatoid ArthritisJosef S Smolen, Eugen Feist, Saeed Fatenejad, et al.
Arthritis Research & Therapy|November 14, 2025
The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trialEugen Feist, Michael E Luggen, Evgeny L Nasonov, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|June 9, 2025
Targeting interleukin-1 signaling for renoprotectionDaria Bogdanova, Mikhail Y Samsonov, Svetlana Lebedeva, et al.
Frontiers in Immunology|December 26, 2024
Targeting inerleukin-6 for renoprotectionEkaterina O Gubernatorova, Mikhail Y Samsonov, Marina S Drutskaya, et al.
The New England Journal of Medicine|August 24, 2022
Olokizumab versus Placebo or Adalimumab in Rheumatoid ArthritisJosef S Smolen, Eugen Feist, Saeed Fatenejad, et al.
Arthritis Research & Therapy|November 14, 2025
The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trialEugen Feist, Michael E Luggen, Evgeny L Nasonov, et al.
Pageof 1